Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2011 AND VI 29 AND IP 1
Results: 26
1
2
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
- Published in:
- 2011
- By:
- Publication type:
- journal article
3
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
- Published in:
- 2011
- By:
- Publication type:
- journal article
4
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
- Published in:
- 2011
- By:
- Publication type:
- journal article
5
Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
- Published in:
- 2011
- By:
- Publication type:
- journal article
6
The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
- Published in:
- 2011
- By:
- Publication type:
- journal article
7
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
8
Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 63, doi. 10.2165/11539190-000000000-00000
- By:
- Publication type:
- Article
9
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
- Published in:
- 2011
- By:
- Publication type:
- journal article
10
Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.
- Published in:
- 2011
- By:
- Publication type:
- journal article
11
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
- Published in:
- 2011
- By:
- Publication type:
- journal article
12
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
- Published in:
- 2011
- By:
- Publication type:
- journal article
13
The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
- Published in:
- 2011
- By:
- Publication type:
- journal article
14
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.
- Published in:
- 2011
- By:
- Publication type:
- journal article
15
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
- Published in:
- 2011
- By:
- Publication type:
- journal article
16
Effects of Reference Pricing in Pharmaceutical Markets: A Review.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 17, doi. 10.2165/11537860-000000000-00000
- By:
- Publication type:
- Article
17
The Authors’ Reply.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 84, doi. 10.2165/11585510-000000000-00000
- By:
- Publication type:
- Article
18
Effects of reference pricing in pharmaceutical markets: a review.
- Published in:
- 2011
- By:
- Publication type:
- journal article
19
Calibrating Models in Economic Evaluation: A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 51, doi. 10.2165/11584610-000000000-00000
- By:
- Publication type:
- Article
20
Calibrating Models in Economic Evaluation: A Seven-Step Approach.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 35, doi. 10.2165/11584600-000000000-00000
- By:
- Publication type:
- Article
21
Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 63, doi. 10.2165/11539190-000000000-00000
- By:
- Publication type:
- Article
22
Is There a Role for Pharmacoeconomics in Developing Countries?
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 83, doi. 10.2165/11585790-000000000-00000
- By:
- Publication type:
- Article
23
Calibrating Models in Economic Evaluation: A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 51, doi. 10.2165/11584610-000000000-00000
- By:
- Publication type:
- Article
24
Calibrating Models in Economic Evaluation: A Seven-Step Approach.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 35, doi. 10.2165/11584600-000000000-00000
- By:
- Publication type:
- Article
25
Effects of Reference Pricing in Pharmaceutical Markets: A Review.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 17, doi. 10.2165/11537860-000000000-00000
- By:
- Publication type:
- Article
26
Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 1, p. 1, doi. 10.2165/11584230-000000000-00000
- By:
- Publication type:
- Article